Table 1.
Baseline characteristics of children at enrolment in a clinical trial of the efficacy of three artemisinin-containing combinations therapies with amodiaquine + sulphadoxine–pyrimathamine (AQ-SP)
|
AS-SMP |
AS-AQ |
AL |
AQ-SP |
p | |
|---|---|---|---|---|---|
| N = 58 | N = 68 | N = 60 | N = 65 | ||
| Age (months) |
|
|
|
|
0.396 |
| Median |
43 |
34 |
40 |
36 |
|
| Interquartile range |
27-51 |
25-49 |
27-48 |
23-52 |
|
| Minimum, maximum |
7-59 |
7-59 |
3-58 |
2-59 |
|
| Gender |
|
|
|
|
0.235 |
| Male (n (%)) |
27 (47%) |
39 (57%) |
38 (63%) |
32 (49%) |
|
| P. falciparum(/μl) |
|
|
|
|
0.853 |
| Median |
17 000 |
18 509 |
16 471 |
14 400 |
|
| Interquartile range |
8200-60 000 |
6480-9 814 |
7200-58917 |
8000-36 000 |
|
| Temperature at day 0 (°C) |
|
|
|
|
0.198 |
| Median |
38,7 |
38.9 |
39.2 |
39.1 |
|
| Interquartile range | 38.3-39.7 | 38.3-39.9 | 38.4-40.2 | 38.4-39.7 |
AS-SMP, Artesunate + sulphamethoxypyrazine-pyrimethamine (Coarinate®); AS-AQ, Artesunate + amodiaquine (Coarsucam®); AL, Artemether + lumefantrine (Coartem®); AQ + SP, Amodiaquine + sulphadoxine-pyrimethamine; N, Effective number.